Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: CPT-184; LBQ 707; NVP-LBQ707; ST-1481

Latest Information Update: 25 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Istituto Nazionale per lo Studio e la Cura dei Tumori; sigma-tau SpA
  • Developer Lee's Pharmaceutical; Novartis; sigma-tau SpA
  • Class Antineoplastics; Benzylisoquinolines; Camptothecins; Heterocyclic compounds with 4 or more rings; Imines; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Discontinued Glioma; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 11 Jul 2019 Phase-I clinical trials in Fallopian tube cancer (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT04029909)
  • 11 Jul 2019 Phase-I clinical trials in Ovarian cancer (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT04029909)
  • 11 Jul 2019 Phase-I clinical trials in Peritoneal cancer (First-line therapy) in China (PO) (NCT04029909)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top